ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

c-Met Inhibitor ANS014004

Also written as “ANS014004” and “ANS014004 + PLB1004”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageC-Met Inhibitor ANS014004: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 27, 20243 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Avistone Biotechnologyits history only22 open or runningphase 1since Feb 27, 2024Feb 27, 2024Apr 2027phase 1 · NCT06307795
Beijing Pearl Biotechnology Limited Liability11 open or runningphase 2since Nov 4, 2025Nov 4, 2025Dec 2029phase 2 · NCT07285148

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Beijing Pearl Biotechnology Limited Liability only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07285148 · 253 planned · United States

Ahead

  1. Dec 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07285148

TargetBeta

MET →read by rule
“An orally bioavailable, next-generation, type II inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
glumetinibruleHaihe Biopharmaphase 39
vebreltinibruleBeijing Pearl Biotechnology Limited Liabilityphase 39
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27

Studies

The one study Beijing Pearl Biotechnology Limited Liability leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07285148Carcinoma, Non-Small-Cell Lung · United States2Not yet recruitingDec 2029253

How it is read

Names in the registry

  • “ANS014004”, 2 entries
  • “ANS014004 + PLB1004”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.